8.41
-0.08 (-0.94%)
| 前收盘价格 | 8.49 |
| 收盘价格 | 8.50 |
| 成交量 | 202,306 |
| 平均成交量 (3个月) | 590,320 |
| 市值 | 440,290,720 |
| 预期市盈率 (P/E Forward) | 10.63 |
| 价格/销量 (P/S) | 7.55 |
| 股市价格/股市净资产 (P/B) | 1.36 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2026 |
| 营业毛利率 | -79.94% |
| 营业利益率 (TTM) | -2,318.99% |
| 稀释每股收益 (EPS TTM) | -2.05 |
| 季度收入增长率 (YOY) | 5,556.00% |
| 总债务/股东权益 (D/E MRQ) | 2.33% |
| 流动比率 (MRQ) | 9.00 |
| 营业现金流 (OCF TTM) | -130.36 M |
| 杠杆自由现金流 (LFCF TTM) | -35.38 M |
| 资产报酬率 (ROA TTM) | -15.49% |
| 股东权益报酬率 (ROE TTM) | -23.46% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Prothena Corporation plc | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -2.5 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.75 |
|
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 18.99% |
| 机构持股比例 | 74.34% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Rubric Capital Management Lp | 31 Mar 2026 | 5,000,000 |
| Palo Alto Investors Lp | 31 Mar 2026 | 1,208,568 |
| Jacobs Levy Equity Management, Inc | 31 Mar 2026 | 972,017 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| ISAACS MICHAEL JOHN | - | 8.56 | -13,080 | -111,965 |
| KINGSTON ANNE EVANS | - | 8.56 | -11,160 | -95,530 |
| KINNEY GENE G. | - | 8.56 | -84,000 | -719,040 |
| NGUYEN TRAN | - | 8.56 | -57,000 | -487,920 |
| SMITH BRANDON S. | - | 8.56 | -78,000 | -667,680 |
| SWANSON CHAD J. | - | 8.56 | -44,267 | -378,926 |
| WALKER KARIN L | - | 8.56 | -15,000 | -128,400 |
| ZAGO WAGNER M. | - | 8.56 | -51,000 | -436,560 |
| 累积净数量 | -353,507 | |||
| 累积净值 ($) | -3,026,020 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 8.56 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| ISAACS MICHAEL JOHN | 职员 | 29 Jul 2026 | 自动卖出 (-) | 8,386 | 8.56 | 71,784 |
| KINGSTON ANNE EVANS | 职员 | 29 Jul 2026 | 自动卖出 (-) | 7,662 | 8.56 | 65,587 |
| ISAACS MICHAEL JOHN | 职员 | 28 Jul 2026 | 处理 (-) | 4,694 | 8.56 | 40,181 |
| KINGSTON ANNE EVANS | 职员 | 28 Jul 2026 | 处理 (-) | 3,498 | 8.56 | 29,943 |
| KINNEY GENE G. | 职员 | 28 Jul 2026 | 处理 (-) | 84,000 | 8.56 | 719,040 |
| KINNEY GENE G. | 职员 | 28 Jul 2026 | 执行期权 | 84,000 | - | - |
| NGUYEN TRAN | 职员 | 28 Jul 2026 | 处理 (-) | 57,000 | 8.56 | 487,920 |
| NGUYEN TRAN | 职员 | 28 Jul 2026 | 执行期权 | 57,000 | - | - |
| SMITH BRANDON S. | 职员 | 28 Jul 2026 | 处理 (-) | 78,000 | 8.56 | 667,680 |
| SMITH BRANDON S. | 职员 | 28 Jul 2026 | 执行期权 | 78,000 | - | - |
| SWANSON CHAD J. | 职员 | 28 Jul 2026 | 处理 (-) | 44,267 | 8.56 | 378,926 |
| SWANSON CHAD J. | 职员 | 28 Jul 2026 | 执行期权 | 51,000 | - | - |
| WALKER KARIN L | 职员 | 28 Jul 2026 | 处理 (-) | 15,000 | 8.56 | 128,400 |
| WALKER KARIN L | 职员 | 28 Jul 2026 | 执行期权 | 15,000 | - | - |
| ZAGO WAGNER M. | 职员 | 28 Jul 2026 | 处理 (-) | 51,000 | 8.56 | 436,560 |
| ZAGO WAGNER M. | 职员 | 28 Jul 2026 | 执行期权 | 51,000 | - | - |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合